Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF (sweat tests/genotype)~* The subject, or their legal guardian for children under 18 years old, must provide written informed consent.~* The subject must be in stable clinical condition at the time of and for a period of 14 days prior to their recruitment into the study.~* Age \> 6 years old~* FEV1 \> 40% predicted for height, age and gender~* Proven or anticipated compliance with therapy or study protocol~* Regular attendee at a Cystic Fibrosis Clinic (\> 2 visits per year)~* Able to reproducibly perform lung function tests (spirometry)~* Relatively stable nutritional status (\< 2 kg weight loss in last 6 months and \< 5 kg weight loss in last year)~* Known to have normal (for CF subject) laboratory tests - haematology, biochemistry, immunology, coagulation, etc.~Exclusion Criteria:~* Requiring home oxygen (pO2 \<55mmHg or pCO2 \>50mmHg) or assisted ventilation.~* Considered terminally ill or listed for transplantation (either lung or liver). Subjects that are listed for transplant after being enrolled in the trial are eligible to continue in the trial.~* Subjects colonised with Burkholderia cepacia. However, if a subject becomes colonised with B. cepacia during the trial, they should continue in the trial. Subjects should be considered to be B. cepacia positive if they have had even a single lifetime isolate. In these subjects, spirometry should be measured on a dedicated spirometer.~* Cigarette smoker.~* Exposure to investigational drugs within the past 30 days.~* Major haemoptysis (\> 60 mL in a single episode) within the last twelve months.~* Concurrent illnesses eg. cor pulmonale, clinically significant liver disease (portal hypertension, varices).~* Known allergy to quinine sulphate, Glucose 6-phosphate dehydrogenase deficiency.~* Immune thrombocytopaenic purpura.~* Pregnant or lactating females.~* At risk females unwilling to use appropriate contraception to prevent pregnancy for the duration of their enrolment in the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).